The University of Southampton
University of Southampton Institutional Repository

Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer

Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer
Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer
Aims: a retrospective analysis was carried out of 291 cases of oesophageal cancer treated with definitive chemoradiotherapy (dCRT) at a single UK cancer centre between 1995 and 2009. Our protocol consisted of two cycles of neoadjuvant platinum-based chemotherapy followed by two further cycles given concurrently with 50 Gy of external beam radiotherapy delivered in 25 fractions over 5 weeks.

Materials and methods: demographic, patient and outcome data were recorded prospectively through an electronic health record and retrospectively analysed, using appropriate statistical tools.

Results: data on 266 patients were available for analysis. The median age was 66.6 years, 53% were adenocarcinomas. dCRT was used instead of surgery because of age/co-morbidity in 44% and disease extent in 39%. Ninety-three per cent of patients completed treatment according to protocol. Grade 3 and 4 toxicities were seen in 42 and 7%, respectively. Median survival was 20.6 months; 2, 3 and 5 year survival rates were 43.6, 32.9 and 19.5%, respectively. Advanced disease was associated with a worse outcome. Shorter disease length was associated with a better median survival, but some patients with disease >10 cm had long-term disease control. The effect of other patient- and disease-related factors was also analysed.

Conclusion: we present data showing that dCRT is well tolerated and should be considered as an alternative to surgery for all patients with locally advanced oesophageal cancer, not only those with co-morbidity. Furthermore, the benefits of dCRT are not confined to carcinomas with squamous histology.
0936-6555
182-188
Gwynne, S.
0cbce6d8-328d-430e-9f5e-a5885deedac8
Hurt, C.
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Evans, M.
0f6f0051-a1c3-47d2-9533-566c6a542e8e
Holden, C.
99da8ea9-5b81-4840-94f2-cebd6ad214ac
Vout, L.
654f0715-b987-4a73-aa0d-9e016ba2dd36
Crosby, T.
82fd6364-ad6d-4e24-bb81-e1868258c4e6
et al.
Gwynne, S.
0cbce6d8-328d-430e-9f5e-a5885deedac8
Hurt, C.
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Evans, M.
0f6f0051-a1c3-47d2-9533-566c6a542e8e
Holden, C.
99da8ea9-5b81-4840-94f2-cebd6ad214ac
Vout, L.
654f0715-b987-4a73-aa0d-9e016ba2dd36
Crosby, T.
82fd6364-ad6d-4e24-bb81-e1868258c4e6

et al. (2011) Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer. Clinical Oncology, 23 (3), 182-188. (doi:10.1016/j.clon.2010.12.001).

Record type: Article

Abstract

Aims: a retrospective analysis was carried out of 291 cases of oesophageal cancer treated with definitive chemoradiotherapy (dCRT) at a single UK cancer centre between 1995 and 2009. Our protocol consisted of two cycles of neoadjuvant platinum-based chemotherapy followed by two further cycles given concurrently with 50 Gy of external beam radiotherapy delivered in 25 fractions over 5 weeks.

Materials and methods: demographic, patient and outcome data were recorded prospectively through an electronic health record and retrospectively analysed, using appropriate statistical tools.

Results: data on 266 patients were available for analysis. The median age was 66.6 years, 53% were adenocarcinomas. dCRT was used instead of surgery because of age/co-morbidity in 44% and disease extent in 39%. Ninety-three per cent of patients completed treatment according to protocol. Grade 3 and 4 toxicities were seen in 42 and 7%, respectively. Median survival was 20.6 months; 2, 3 and 5 year survival rates were 43.6, 32.9 and 19.5%, respectively. Advanced disease was associated with a worse outcome. Shorter disease length was associated with a better median survival, but some patients with disease >10 cm had long-term disease control. The effect of other patient- and disease-related factors was also analysed.

Conclusion: we present data showing that dCRT is well tolerated and should be considered as an alternative to surgery for all patients with locally advanced oesophageal cancer, not only those with co-morbidity. Furthermore, the benefits of dCRT are not confined to carcinomas with squamous histology.

This record has no associated files available for download.

More information

Accepted/In Press date: 29 November 2010
e-pub ahead of print date: 12 January 2011
Published date: April 2011

Identifiers

Local EPrints ID: 488376
URI: http://eprints.soton.ac.uk/id/eprint/488376
ISSN: 0936-6555
PURE UUID: 94af124b-003e-488e-b763-a1e2eed5c92e
ORCID for C. Hurt: ORCID iD orcid.org/0000-0003-1206-8355

Catalogue record

Date deposited: 21 Mar 2024 17:33
Last modified: 23 Mar 2024 03:13

Export record

Altmetrics

Contributors

Author: S. Gwynne
Author: C. Hurt ORCID iD
Author: M. Evans
Author: C. Holden
Author: L. Vout
Author: T. Crosby
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×